// App-Quantinova.ai

: TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Claudia Pérez Carretero

Principal Investigators

  • Miguel Quijada Álamo

  • Mariana Tannoury

  • Léa Dehgane

  • David J. Sanz

  • Teresa Gonzalez

  • Rocio Benito

  • Elise Chapiro

  • Maria Hernandez-Sanchez

  • Ana E. Rodriguez

  • Florence NGuyen Khac

  • Santos A. Susin

  • Jesus Maria Hernandez-Rivas

Medical Centers

  • University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain

  • Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain

  • Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

  • Hematology Department, University Hospital of Salamanca, Salamanca, Spain

  • Drug Resistance in Hematological Malignancies, Centre de Recherche des Cordeliers, UMRS , INSERM, Sorbonne Université, Université Paris Cité; Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France

  • Universidad de Salamanca, IBSAL, Centro de Investigación del Cáncer, IBMCC-CSIC, Salamanca, Spain

  • Department of Medicine, University Hospital of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain

  • Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain

  • Drug Resistance in Hematological Malignancies, Centre de Recherche des Cordeliers, UMRS , INSERM, Sorbonne Université, Université Paris Cité, Paris, France

  • Department of Hematology, University Hospital of Salamanca, Salamanca, Spain

  • Cancer Research Center (IBMCC) CSIC, University of Salamanca, Salamanca, Spain

  • Laboratory of Hematology, Hopital Pitie-Salpetriere, UPMC Paris , INSERMU, Paris, France

Locations

  • Spain

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • B cell lymphomas

  • Multiple Myeloma

  • Tuberculosis

  • Lymphomas

Biomarkers

  • BCL2 associated X, apoptosis regulator

  • Tumor necrosis factor

Drug/Treatment

  • 2-Deoxy-D-Glucose

  • Venetoclax

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved